OncoVITA is a biotechnology company based out of 28 RUE DU DOCTEUR ROUX, PARIS, France.

OncoVITA

OncoVITA raised $8,741,000-Congrats Jean-Francois Le Bigot, PhD
Full Round Info: https://lnkd.in/gpVkW8CT
Round Investors: Private Investors and Business Angels

Oncovita raise 8M€ to support the development of its MVdeltaC immunotherapeutic vaccine in oncology

#MONEYTIME 
OncoVITA décroche 8M€ de financements. Cette biotech francilienne, spin-off de l’Institut Pasteur, cible les tumeurs solides avec MVdeltaC un candidat vaccin immuno-thérapeutique utilisant le virus de la rougeole. Dirigée par Jean-Francois Le Bigot, PhD  (ex-Citoxlab), Oncovita a collecté 4,5 M€ en subvention et prêt dans le cadre du plan d’investissement France 2030 opéré par Bpifrance et 3,5 M€ en provenance d’investisseurs privés. Les fonds permettront notamment la production d’un premier lot clinique de MVdeltaC, puis l’initiation d’un essai clinique de phase 1/2a dans des tumeurs solides courant 2025. Plus d’infos dans #BiotechFinances n°1050 à paraître ce vendredi. 

#AnnonceWebinaire  : mardi 5 décembre à 19H avec Pierre D’EPENOUX (CEO d’IMCHECK) et Marina ICHÉ (CEO d’ILIFE). "ImCheck & ILife : le développement clinique, pilier du succès !" La stratégie clinique et son exécution opérationnelle dans la biotech. L’exemple d’ImCheck Therapeutics, en dialogue avec son partenaire de la 1ère heure, ILife Consulting. Inscription gratuite : https://lnkd.in/eUNuNUdr
 
#BioMapFrance2024. N'oubliez pas de remplir le formulaire avant le 31/12/2023 pour figurer gratuitement sur le poster BioMap France 2024 qui sera publié en janvier prochain ! Lien : https://lnkd.in/efGVY8Mp


Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells
Cancer Immunol Immunother. 2023 Oct;72(10):3309-3322. 

In this study, we show that the attenuated Schwarz MV encoding human NY-ESO-1 is able to express this tumor antigen in infected melanoma tumor cells, while retaining its oncolytic activity. Upon infection of melanoma cells, NY-ESO-1 is strongly expressed and NY-ESO-1 peptides are efficiently presented by infected tumor cells to specific CD8 + and CD4 + T cells by HLA class I and II molecules. We also show that MVny replicates modestly in monocyte-derived DCs compared to melanoma cells, allowing DCs to present NY-ESO-1 peptides to specific CD4 + and CD8 + T cells. Altogether, these results demonstrate that MVny displays an oncolytic activity against melanoma cell lines and induces NY-ESO-1 peptides presentation not only by tumor cells, but also by antigen presenting cells such as monocyte-derived DCs.


Veristat is a company specializing in oncolytic virotherapy and gene therapy.

Veristat

Chameleon is involved in virus vector technology, including oncolytic virotherapy.

Chameleon

Elicera is focused on clinical CAR-T cell and oncolytic virotherapy for cancer treatment.

Elicera

Oncovita is a biotechnology company specializing in the development of innovative treatments for cancer. The company leverages its proprietary technology platform, which is based on the use of recombinant measles virus, to create targeted oncolytic virotherapies. Oncovita's approach aims to harness the potential of virotherapy to selectively destroy cancer cells while sparing healthy tissues.

Oncovita

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 8:39 AM	fea6ffc1
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 14, 2024 8:39 AM	588beb3d
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

FR:ONCOVITA

Oncovita